Loading…

Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis

The clinical applications of etanercept (Enbrel), an emerging therapeutic protein for rheumatoid arthritis (RA), are limited by its instability and low bioavailability. In this study, a long-term and efficient therapeutic nanocomplex formulation for RA treatment was developed in the form of a temper...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2013-10, Vol.171 (2), p.143-151
Main Authors: Jung, Young-Seok, Park, Wooram, Na, Kun
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843
cites cdi_FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843
container_end_page 151
container_issue 2
container_start_page 143
container_title Journal of controlled release
container_volume 171
creator Jung, Young-Seok
Park, Wooram
Na, Kun
description The clinical applications of etanercept (Enbrel), an emerging therapeutic protein for rheumatoid arthritis (RA), are limited by its instability and low bioavailability. In this study, a long-term and efficient therapeutic nanocomplex formulation for RA treatment was developed in the form of a temperature-modulated noncovalent interaction controllable (TMN) complex based on a temperature-sensitive amphiphilic polyelectrolyte (succinylated pullulan-g-oligo(l-lactide); SPL). The TMN complexes were prepared by simply mixing the negatively charged SPL copolymer and the positively charged etanercept via electrostatic interaction at 4°C below the polymer's clouding temperature (CT), and the resulting complex demonstrated significantly improved salt and serum stability with increased hydrophobic interactions at temperatures (physiological condition, 37.5°C) above the CT. An in vitro study of the bioactivity of etanercept indicated that the TMN complex improves the long-term stability of etanercept in an aqueous environment because of the exposure of the functional active site and the molecular chaperone-like effect of the hydrophobic copolymer. This formulation possessed prolonged in vivo pharmacokinetic parameters. In a collagen-induced arthritis RA rat model, we verified the outstanding therapeutic effect of the TMN complexes. These results imply that this approach would be widely applied to protein and peptide delivery systems. Temperature-modulated noncovalent interaction controllable (TMN) complex, the noncovalent interaction between polymer and therapeutic protein was enhanced by increasing temperature. The TMN complex showed significantly improved salt and serum stability at physiological temperature (37.5°C). [Display omitted]
doi_str_mv 10.1016/j.jconrel.2013.07.012
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1500772821</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365913004069</els_id><sourcerecordid>1500772821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843</originalsourceid><addsrcrecordid>eNqFkc9u1DAQxiMEotvCIwA-cknwv8TJCaEKKFIlDrRny7EnXa8cO9jOqn0E3hpHu3DtaTSj38z32V9VvSO4IZh0nw7NQQcfwTUUE9Zg0WBCX1Q70gtW82FoX1a7wvU169rhorpM6YAxbhkXr6sLyvoec0F21Z87mBeIKq8R6jmY1akMBvngdTgqBz4j63MBdLbBoyKZY3BOjQ5KMy8OHtEUIsp7QC74h7qwMzLg7BHiEwoTgqw8RA1LRjmgHEFlFPewzioHa5CKeR9ttulN9WpSLsHbc72q7r99vbu-qW9_fv9x_eW21pzSXI8tG8eOjlqIVuCRYo6nllA6DUYwQ_SExTZsR26mQQAD1m-F884YUD1nV9XH090lht8rpCxnmzSUN3kIa5KkxVgI2lPyPMoZ6chA26Gg7QnVMaQUYZJLtLOKT5JguQUmD_IcmNwCk1jIEljZe3-WWMcZzP-tfwkV4MMJmFSQ6iHaJO9_lQvFJSk22Sb9-URA-bWjhSiTtuA1GBtBZ2mCfcbEX_nrtlk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1431619259</pqid></control><display><type>article</type><title>Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Jung, Young-Seok ; Park, Wooram ; Na, Kun</creator><creatorcontrib>Jung, Young-Seok ; Park, Wooram ; Na, Kun</creatorcontrib><description>The clinical applications of etanercept (Enbrel), an emerging therapeutic protein for rheumatoid arthritis (RA), are limited by its instability and low bioavailability. In this study, a long-term and efficient therapeutic nanocomplex formulation for RA treatment was developed in the form of a temperature-modulated noncovalent interaction controllable (TMN) complex based on a temperature-sensitive amphiphilic polyelectrolyte (succinylated pullulan-g-oligo(l-lactide); SPL). The TMN complexes were prepared by simply mixing the negatively charged SPL copolymer and the positively charged etanercept via electrostatic interaction at 4°C below the polymer's clouding temperature (CT), and the resulting complex demonstrated significantly improved salt and serum stability with increased hydrophobic interactions at temperatures (physiological condition, 37.5°C) above the CT. An in vitro study of the bioactivity of etanercept indicated that the TMN complex improves the long-term stability of etanercept in an aqueous environment because of the exposure of the functional active site and the molecular chaperone-like effect of the hydrophobic copolymer. This formulation possessed prolonged in vivo pharmacokinetic parameters. In a collagen-induced arthritis RA rat model, we verified the outstanding therapeutic effect of the TMN complexes. These results imply that this approach would be widely applied to protein and peptide delivery systems. Temperature-modulated noncovalent interaction controllable (TMN) complex, the noncovalent interaction between polymer and therapeutic protein was enhanced by increasing temperature. The TMN complex showed significantly improved salt and serum stability at physiological temperature (37.5°C). [Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2013.07.012</identifier><identifier>PMID: 23880471</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>active sites ; animal models ; Animals ; Antirheumatic Agents - administration &amp; dosage ; Antirheumatic Agents - chemistry ; Antirheumatic Agents - pharmacokinetics ; Arthritis, Experimental ; Arthritis, Rheumatoid - blood ; Arthritis, Rheumatoid - drug therapy ; Bioavailability ; blood serum ; Cell Line, Tumor ; composite polymers ; Drug delivery ; Drug Delivery Systems ; electrolytes ; Electrostatic interactions ; Etanercept ; Female ; Glucans - chemistry ; hydrophobic bonding ; hydrophobicity ; Immunoglobulin G - administration &amp; dosage ; Immunoglobulin G - chemistry ; in vitro studies ; Mice ; mixing ; Noncovalent interactions ; pharmacokinetics ; Polyesters - chemistry ; Rats ; Rats, Inbred Lew ; Receptors, Tumor Necrosis Factor - administration &amp; dosage ; Receptors, Tumor Necrosis Factor - chemistry ; Rheumatoid arthritis ; Temperature ; therapeutics ; Tumor Necrosis Factor-alpha - metabolism</subject><ispartof>Journal of controlled release, 2013-10, Vol.171 (2), p.143-151</ispartof><rights>2013 Elsevier B.V.</rights><rights>2013 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843</citedby><cites>FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23880471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jung, Young-Seok</creatorcontrib><creatorcontrib>Park, Wooram</creatorcontrib><creatorcontrib>Na, Kun</creatorcontrib><title>Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>The clinical applications of etanercept (Enbrel), an emerging therapeutic protein for rheumatoid arthritis (RA), are limited by its instability and low bioavailability. In this study, a long-term and efficient therapeutic nanocomplex formulation for RA treatment was developed in the form of a temperature-modulated noncovalent interaction controllable (TMN) complex based on a temperature-sensitive amphiphilic polyelectrolyte (succinylated pullulan-g-oligo(l-lactide); SPL). The TMN complexes were prepared by simply mixing the negatively charged SPL copolymer and the positively charged etanercept via electrostatic interaction at 4°C below the polymer's clouding temperature (CT), and the resulting complex demonstrated significantly improved salt and serum stability with increased hydrophobic interactions at temperatures (physiological condition, 37.5°C) above the CT. An in vitro study of the bioactivity of etanercept indicated that the TMN complex improves the long-term stability of etanercept in an aqueous environment because of the exposure of the functional active site and the molecular chaperone-like effect of the hydrophobic copolymer. This formulation possessed prolonged in vivo pharmacokinetic parameters. In a collagen-induced arthritis RA rat model, we verified the outstanding therapeutic effect of the TMN complexes. These results imply that this approach would be widely applied to protein and peptide delivery systems. Temperature-modulated noncovalent interaction controllable (TMN) complex, the noncovalent interaction between polymer and therapeutic protein was enhanced by increasing temperature. The TMN complex showed significantly improved salt and serum stability at physiological temperature (37.5°C). [Display omitted]</description><subject>active sites</subject><subject>animal models</subject><subject>Animals</subject><subject>Antirheumatic Agents - administration &amp; dosage</subject><subject>Antirheumatic Agents - chemistry</subject><subject>Antirheumatic Agents - pharmacokinetics</subject><subject>Arthritis, Experimental</subject><subject>Arthritis, Rheumatoid - blood</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Bioavailability</subject><subject>blood serum</subject><subject>Cell Line, Tumor</subject><subject>composite polymers</subject><subject>Drug delivery</subject><subject>Drug Delivery Systems</subject><subject>electrolytes</subject><subject>Electrostatic interactions</subject><subject>Etanercept</subject><subject>Female</subject><subject>Glucans - chemistry</subject><subject>hydrophobic bonding</subject><subject>hydrophobicity</subject><subject>Immunoglobulin G - administration &amp; dosage</subject><subject>Immunoglobulin G - chemistry</subject><subject>in vitro studies</subject><subject>Mice</subject><subject>mixing</subject><subject>Noncovalent interactions</subject><subject>pharmacokinetics</subject><subject>Polyesters - chemistry</subject><subject>Rats</subject><subject>Rats, Inbred Lew</subject><subject>Receptors, Tumor Necrosis Factor - administration &amp; dosage</subject><subject>Receptors, Tumor Necrosis Factor - chemistry</subject><subject>Rheumatoid arthritis</subject><subject>Temperature</subject><subject>therapeutics</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqFkc9u1DAQxiMEotvCIwA-cknwv8TJCaEKKFIlDrRny7EnXa8cO9jOqn0E3hpHu3DtaTSj38z32V9VvSO4IZh0nw7NQQcfwTUUE9Zg0WBCX1Q70gtW82FoX1a7wvU169rhorpM6YAxbhkXr6sLyvoec0F21Z87mBeIKq8R6jmY1akMBvngdTgqBz4j63MBdLbBoyKZY3BOjQ5KMy8OHtEUIsp7QC74h7qwMzLg7BHiEwoTgqw8RA1LRjmgHEFlFPewzioHa5CKeR9ttulN9WpSLsHbc72q7r99vbu-qW9_fv9x_eW21pzSXI8tG8eOjlqIVuCRYo6nllA6DUYwQ_SExTZsR26mQQAD1m-F884YUD1nV9XH090lht8rpCxnmzSUN3kIa5KkxVgI2lPyPMoZ6chA26Gg7QnVMaQUYZJLtLOKT5JguQUmD_IcmNwCk1jIEljZe3-WWMcZzP-tfwkV4MMJmFSQ6iHaJO9_lQvFJSk22Sb9-URA-bWjhSiTtuA1GBtBZ2mCfcbEX_nrtlk</recordid><startdate>20131028</startdate><enddate>20131028</enddate><creator>Jung, Young-Seok</creator><creator>Park, Wooram</creator><creator>Na, Kun</creator><general>Elsevier B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20131028</creationdate><title>Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis</title><author>Jung, Young-Seok ; Park, Wooram ; Na, Kun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>active sites</topic><topic>animal models</topic><topic>Animals</topic><topic>Antirheumatic Agents - administration &amp; dosage</topic><topic>Antirheumatic Agents - chemistry</topic><topic>Antirheumatic Agents - pharmacokinetics</topic><topic>Arthritis, Experimental</topic><topic>Arthritis, Rheumatoid - blood</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Bioavailability</topic><topic>blood serum</topic><topic>Cell Line, Tumor</topic><topic>composite polymers</topic><topic>Drug delivery</topic><topic>Drug Delivery Systems</topic><topic>electrolytes</topic><topic>Electrostatic interactions</topic><topic>Etanercept</topic><topic>Female</topic><topic>Glucans - chemistry</topic><topic>hydrophobic bonding</topic><topic>hydrophobicity</topic><topic>Immunoglobulin G - administration &amp; dosage</topic><topic>Immunoglobulin G - chemistry</topic><topic>in vitro studies</topic><topic>Mice</topic><topic>mixing</topic><topic>Noncovalent interactions</topic><topic>pharmacokinetics</topic><topic>Polyesters - chemistry</topic><topic>Rats</topic><topic>Rats, Inbred Lew</topic><topic>Receptors, Tumor Necrosis Factor - administration &amp; dosage</topic><topic>Receptors, Tumor Necrosis Factor - chemistry</topic><topic>Rheumatoid arthritis</topic><topic>Temperature</topic><topic>therapeutics</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jung, Young-Seok</creatorcontrib><creatorcontrib>Park, Wooram</creatorcontrib><creatorcontrib>Na, Kun</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jung, Young-Seok</au><au>Park, Wooram</au><au>Na, Kun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2013-10-28</date><risdate>2013</risdate><volume>171</volume><issue>2</issue><spage>143</spage><epage>151</epage><pages>143-151</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>The clinical applications of etanercept (Enbrel), an emerging therapeutic protein for rheumatoid arthritis (RA), are limited by its instability and low bioavailability. In this study, a long-term and efficient therapeutic nanocomplex formulation for RA treatment was developed in the form of a temperature-modulated noncovalent interaction controllable (TMN) complex based on a temperature-sensitive amphiphilic polyelectrolyte (succinylated pullulan-g-oligo(l-lactide); SPL). The TMN complexes were prepared by simply mixing the negatively charged SPL copolymer and the positively charged etanercept via electrostatic interaction at 4°C below the polymer's clouding temperature (CT), and the resulting complex demonstrated significantly improved salt and serum stability with increased hydrophobic interactions at temperatures (physiological condition, 37.5°C) above the CT. An in vitro study of the bioactivity of etanercept indicated that the TMN complex improves the long-term stability of etanercept in an aqueous environment because of the exposure of the functional active site and the molecular chaperone-like effect of the hydrophobic copolymer. This formulation possessed prolonged in vivo pharmacokinetic parameters. In a collagen-induced arthritis RA rat model, we verified the outstanding therapeutic effect of the TMN complexes. These results imply that this approach would be widely applied to protein and peptide delivery systems. Temperature-modulated noncovalent interaction controllable (TMN) complex, the noncovalent interaction between polymer and therapeutic protein was enhanced by increasing temperature. The TMN complex showed significantly improved salt and serum stability at physiological temperature (37.5°C). [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>23880471</pmid><doi>10.1016/j.jconrel.2013.07.012</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0168-3659
ispartof Journal of controlled release, 2013-10, Vol.171 (2), p.143-151
issn 0168-3659
1873-4995
language eng
recordid cdi_proquest_miscellaneous_1500772821
source Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)
subjects active sites
animal models
Animals
Antirheumatic Agents - administration & dosage
Antirheumatic Agents - chemistry
Antirheumatic Agents - pharmacokinetics
Arthritis, Experimental
Arthritis, Rheumatoid - blood
Arthritis, Rheumatoid - drug therapy
Bioavailability
blood serum
Cell Line, Tumor
composite polymers
Drug delivery
Drug Delivery Systems
electrolytes
Electrostatic interactions
Etanercept
Female
Glucans - chemistry
hydrophobic bonding
hydrophobicity
Immunoglobulin G - administration & dosage
Immunoglobulin G - chemistry
in vitro studies
Mice
mixing
Noncovalent interactions
pharmacokinetics
Polyesters - chemistry
Rats
Rats, Inbred Lew
Receptors, Tumor Necrosis Factor - administration & dosage
Receptors, Tumor Necrosis Factor - chemistry
Rheumatoid arthritis
Temperature
therapeutics
Tumor Necrosis Factor-alpha - metabolism
title Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T11%3A09%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Temperature-modulated%20noncovalent%20interaction%20controllable%20complex%20for%20the%20long-term%20delivery%20of%20etanercept%20to%20treat%20rheumatoid%20arthritis&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Jung,%20Young-Seok&rft.date=2013-10-28&rft.volume=171&rft.issue=2&rft.spage=143&rft.epage=151&rft.pages=143-151&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2013.07.012&rft_dat=%3Cproquest_cross%3E1500772821%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1431619259&rft_id=info:pmid/23880471&rfr_iscdi=true